High-risk human papillomavirus oncoproteins E6 and E7 play a major role in HPV-related cancers. One of the main functions of E7 is the degradation of pRb, while E6 promotes the degradation of p53, inactivating the p14ARF-p53 pathway. pRb and p14ARF can repress ribosomal DNA (rDNA) transcription in part by targeting the Upstream Binding Factor 1 (UBF1), a key factor in the activation of RNA polymerase I machinery. We showed, through ectopic expression and siRNA silencing of p14ARF and/or E7, that E7 stimulates UBF1-mediated rDNA gene transcription, partly because of increased levels of phosphorylated UBF1, preventing the inhibitory function of p14ARF. Unexpectedly, activation of rDNA gene transcription was higher in cells co-expressing p14ARF and E7, compared to cells expressing E7 alone. We did not find a difference in P-UBF1 levels that could explain this data. However, p14ARF expression induced E7 to accumulate into the nucleolus, where rDNA transcription takes place, providing an opportunity for E7 to interact with nucleolar proteins involved in this process. GST-pull down and co-immunoprecipitation assays showed interactions between p14ARF, UBF1 and E7, although p14ARF and E7 are not able to directly interact. Co-expression of a pRb-binding-deficient mutant (E7C24G) and p14ARF resulted in EC24G nucleolar accumulation, but not in a significant higher activation of rDNA transcription, suggesting that the inactivation of pRb is involved in this phenomenon. Thus, p14ARF fails to prevent E7-mediated UBF1 phosphorylation, but could facilitate nucleolar pRb inactivation by targeting E7 to the nucleolus. While others have reported that p19ARF, the mouse homologue of p14ARF, inhibits some functions of E7, we showed that E7 inhibits a p53-independent function of p14ARF. These results point to a mutually functional interaction between p14ARF and E7 that might partly explain why the sustained p14ARF expression observed in most cervical pre-malignant lesions and malignancies may be ineffective.
References
[1]
Zur Hausen H (2009) Papillomaviruses in the causation of human cancers-a brief history account. Virology 384: 260–265.
[2]
Moody CA, Laimins LA (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550–560.
[3]
Sherr CJ, Bertwistle D, Den Besten W, Kuo ML, Sugimoto M, et al. (2005) p53-dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol 70: 129–137.
[4]
Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, et al. (2009) p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 35: 210–220.
[5]
Sano T, Masuda N, Oyama T, Nakajima T (2002) Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int 52: 375–383.
[6]
Wang JL, Zheng BY, Li XD, Nokelainen K, Angstr？m T, et al. (2005) p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Mod Pathol 18: 629–637.
[7]
Bulten J, van der Avoort IA, Melchers WJ, Massuger LF, Grefte JM (2006) Gynecol Oncol. 101: 487–494.
[8]
Vázquez-Vega S, Sánchez-Suárez LP, Contreras-Paredes A, Castellanos-Juárez E, Pe？arroja-Flores R, et al. (2010) Nuclear co-expression of p14ARF and p16INK4A in uterine cervical cancer-derived cell lines containing HPV. Cancer Biomark 8: 341–350.
[9]
Ozenne P, Eymin B, Brambilla E, Gazzeri S (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127: 2239–2247.
[10]
Sekaric P, Shamanin VA, Luo J, Androphy EJ (2007) hAda3 regulates p14ARF-induced p53 acetylation and senescence. Oncogene 26: 6261–6268.
[11]
Thomas MC, Chiang CM (2005) E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 17: 251–264.
[12]
Shamanin VA, Sekaric P, Androphy EJ (2008) hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. J Virol 82: 3912–3920.
[13]
Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, et al. (2010) Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. Mol Cell 38: 700–711.
[14]
Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, et al. (2006) Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 2006 25: 7577–7586.
[15]
Rizos H, McKenzie HA, Ayub AL, Woodruff S, Becker TM, et al. (2006) Physical and functional interaction of the p14ARF tumor suppressor with ribosomes. J Biol Chem 281: 38080–38088.
[16]
Sugimoto M, Kuo ML, Roussel MF, Sherr CJ (2003) Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 11: 415–424.
[17]
Apicelli AJ, Maggi LB Jr, Hirbe AC, Miceli AP, Olanich ME, et al. (2008) A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol Cell Biol 28: 1068–1080.
[18]
Lessard F, Morin F, Ivanchuk S, Langlois F, Stefanovsky V, et al. (2010) The ARF tumor suppressor controls ribosome biogenesis by regulating the RNA polymerase I transcription factor TTF-I. Mol Cell 38: 539–550.
[19]
Saporita AJ, Chang HC, Winkeler CL, Apicelli AJ, Kladney RD, et al. (2011) RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis. Cancer Res 71: 6708–6717.
[20]
Lempi？inen H, Shore D (2009) Growth control and ribosome biogenesis. Curr Opin Cell Biol 21: : 855–863.
[21]
Drygin D, Rice WG, Grummt I (2010) The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu Rev Pharmacol Toxicol 50: 131–156.
[22]
Ayrault O, Andrique L, Séité P (2006) Involvement of the transcriptional factor E2F in the regulation of the rRNA promoter. Exp Cell Res 312(7): 1185–1193.
[23]
Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, et al. (2005) c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7: 311–318.
[24]
Cavanaugh AH, Hempel WM, Taylor LJ, Rogalsky V, Todorov G, et al. (1995) Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374: 177–180.
[25]
Budde A, Grummt I (1999) p53 represses ribosomal gene transcription. Oncogene 18: 1119–1124.
[26]
Ayrault O, Andrique L, Larsen CJ, Seite P (2004) Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 23(49): 8097–8104.
[27]
Ghoshal K, Majumder S, Datta J, Motiwala T, Bai S, et al. (2004) Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression. J Biol Chem 279: 6783–6793.
[28]
Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S (2003) p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 22: 1822–1835.
[29]
Voit R, Kuhn A, Sander EE, Grummt I (1995) Activation of mammalian ribosomal gene transcription requires phosphorylation of the nucleolar transcription factor UBF. Nucleic Acids Res 23: 2593–2599.
[30]
Voit R, Hoffmann M, Grummt I (1999) Phosphorylation by G1-specific cdk-cyclin complexes activates the nucleolar transcription factor UBF. EMBO J 18: 1891–1899.
[31]
Voit R, Grummt I (2001) Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc Natl Acad Sci USA 98: 13631–13636.
[32]
He W, Staples D, Smith C, Fisher C (2003) Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol 77: 10566–10574.
[33]
Pan W, Datta A, Adami GR, Raychaudhuri P, Bagchi S (2003) p19ARF inhibits the functions of the HPV16 E7 oncoprotein. Oncogene 22: 5496–5503.
[34]
Lindstr？m MS (2011) NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling. Biochem Res Int 2011: 195209.
[35]
Zhai W, Tuan JA, Comai L (1997) SV40 large T antigen binds to the TBP-TAF(I) complex SL1 and coactivates ribosomal RNA transcription. Genes Dev 11: 1605–1617.
[36]
Kao CF, Chen SY, Lee YH (2004) Activation of RNA polymerase I transcription by hepatitis C virus core protein. J Biomed Sci 11: 72–94.
[37]
Wang HD, Trivedi A, Johnson DL (1998) Regulation of RNA polymerase I-dependent promoters by the hepatitis B virus X protein via activated Ras and TATA-binding protein. Mol Cell Biol 18: 7086–7094.
[38]
Zhai W, Comai L (1999) A kinase activity associated with simian virus 40 large T antigen phosphorylates upstream binding factor (UBF) and promotes formation of a stable initiation complex between UBF and SL1. Mol Cell Biol 19: 2791–2802.
[39]
Raychaudhuri S, Fontanes V, Barat B, Dasgupta A (2009) Activation of ribosomal RNA transcription by hepatitis C virus involves upstream binding factor phosphorylation via induction of cyclin D1. Cancer Res 69: 2057–2064.
[40]
Sauer K, Lehner C (1995) The role of cyclin E in the regulation of entry into the S phase. Prog Cell Cycle Res1: 125–139.
[41]
Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B, et al. (1995) Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 69: 6389–6399.
[42]
Martin LG, Demers GW, Galloway DA (1998) Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol 72: 975–985.
[43]
Zatsepina O, Braspenning J, Robberson D, Hajibagheri MA, Blight KJ, et al. (1997) The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells. Oncogene 14: 1137–1145..
[44]
Zhai W, Tuan JA, Comai L (1997) SV40 large T antigen binds to the TBP-TAF(I) complex SL1 and coactivates ribosomal RNA transcription. Genes Dev 15: 1605–1617.
[45]
Mazzarelli JM, Atkins GB, Geisberg JV, Ricciardi RP (1995) The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40 TAg bind a common region of the TBP-associated factor-110. Oncogene 11: 1859–1864.
[46]
Massimi P, Pim D, Banks L (1997) Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J Gen Virol 78: 2607–2613.
[47]
Shen J, Zhang S, Li Y, Zhang W, Chen J, et al. (2011) p14(ARF) inhibits the functions of adenovirus E1A oncoprotein. Biochem J 434: 275–285.
[48]
Lindstr？m MS, Zhang Y (2006) B23 and ARF: friends or foes? Cell Biochem Biophys 46: 79–90.
[49]
Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, et al. (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25: 1258–1271.
[50]
Humbey O, Pimkina J, Zilfou JT, Jarnik M, Dominguez-Brauer C, et al. (2008) The ARF tumor suppressor can promote the progression of some tumors. Cancer Res 68: 9608–9613.
[51]
McLaughlin-Drubin M, Park D, Münger K (2013) Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci USA 110: 16175–16180.
[52]
McCloskey R, Menges C, Friedman A, Patel D, McCance DJ (2010) Human papillomavirus type 16 E6/E7 upregulation of nucleophosmin is important for proliferation and inhibition of differentiation. J Virol 84: 5131–5139.
[53]
Ganzenmueller T, Matthaei M, Muench P, Scheible M, Iftner A, et al. (2008) The E7 protein of the cottontail rabbit papillomavirus immortalizes normal rabbit keratinocytes and reduces pRb levels, while E6 cooperates in immortalization but neither degrades p53 nor binds E6AP. Virology 372: 313–324.
[54]
García MA, Collado M, Mu？oz-Fontela C, Matheu A, Marcos-Villar L, et al. (2006) Antiviral action of the tumor suppressor ARF. EMBO J 25: 4284–4292.
[55]
Greco A (2009) Involvement of the nucleolus in replication of human viruses. Rev Med Virol 19: 201–214.
[56]
Storey A, Pim D, Murray A, Osborn K, Banks L, et al. (1988) Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J 7: 1815–1820.
[57]
Baldwin A, Huh KW, Münger K (2006) Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J Virol 80: 6669–6677.
[58]
Accardi R, Rubino R, Scalise M, Gheit T, Shahzad N, et al. (2011) E7 and E7 from Human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol 85: 8208–8216.
